晚期非小细胞肺癌患者使用EGFR-TKI治疗后长期生存情况的研究
|
摘要
目的
探索用常见的表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌(NSCLC)患者,影响长期生存情况的因素,研究长期生存者血清EGFR突变情况。
方法
回顾性分析从2002年12月——2007年6月在北京协和医院进行EGFR-TKI治疗的292例晚期非小细胞肺癌患者,收集所有长期生存(定义为使用吉非替尼或厄洛替尼治疗后存活时间大于3年)患者的相关临床资料(年龄组、性别、组织学、吸烟史、疾病分期、未接受过治疗或已接受过治疗、治疗反应等)进行比较,对其中仍存活的患者进行血清EGFR检测,收集存活患者中已检测过的EGFR突变数据。
结果
EGFR-TKI治疗晚期NSCLC3年生存率16.1%。吸烟史(P=0.033)和病理类型(P=0.006)是与EGFR-TKI治疗生存时间密切相关的因素,而性别(P=0.311)、年龄(P=0.121)、ECOG评分(P=0.299)及临床分期(P=0.235)则与之无显著关系。长期存活患者EGFR敏感突变率65.2%,女性(68.8%)和腺癌(71.4%)突变率最高。
结论
EGFR-TKI是有效的治疗NSCLC的靶向药物,可以改善NSCLC患者的生存时间。根据患者具体情况选择合适肺癌患者并进行吉非替尼治疗可望使肺癌治疗更为个体化,具有更好的临床应用前景。EGFR敏感突变可能能用来预测患者预后。
Objective
To investigate the factors that influence the long-term survival of patients with advanced non-small cell lung cancer(NSCLC) who were treated with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor. And detect the EGFR mutations of these long-term survival patients.
Methods
From December2002to June2007,292patients with advanced NSCLC were enrolled for treatment with EGFR-TKI in Peking Union Medical College Hospital. Clinical data was analyzed by Pearson's Chi-square test. Detect the EGFR mutations of the living patients in the serum samples by DNA sequencing method.
Results
The long-term survival of EGFR-TKI-treated patients had a3-year survival rate of16.1%, which was correlated with smoking history (P=0.033), and pathological type(P=0.006). It was not correlated with gender(P=0.311), age(P=0.121), ECOG score(P=0.299), and clinical stage(P=0.235). EGFR sensitive mutation rate in the serum of long-term survival patients was65.2%, and the mutation rates of female patients (68.8%) and adenocarcinoma patients were higher than the others.
Conclusions
EGFR-TKI offers a new treatment option for advanced NSCLC. EGFR mutation status may have important significance for evaluating the prognosis of advance NSCLC patients treated with EGFR-TKI.
探索用常见的表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌(NSCLC)患者,影响长期生存情况的因素,研究长期生存者血清EGFR突变情况。
方法
回顾性分析从2002年12月——2007年6月在北京协和医院进行EGFR-TKI治疗的292例晚期非小细胞肺癌患者,收集所有长期生存(定义为使用吉非替尼或厄洛替尼治疗后存活时间大于3年)患者的相关临床资料(年龄组、性别、组织学、吸烟史、疾病分期、未接受过治疗或已接受过治疗、治疗反应等)进行比较,对其中仍存活的患者进行血清EGFR检测,收集存活患者中已检测过的EGFR突变数据。
结果
EGFR-TKI治疗晚期NSCLC3年生存率16.1%。吸烟史(P=0.033)和病理类型(P=0.006)是与EGFR-TKI治疗生存时间密切相关的因素,而性别(P=0.311)、年龄(P=0.121)、ECOG评分(P=0.299)及临床分期(P=0.235)则与之无显著关系。长期存活患者EGFR敏感突变率65.2%,女性(68.8%)和腺癌(71.4%)突变率最高。
结论
EGFR-TKI是有效的治疗NSCLC的靶向药物,可以改善NSCLC患者的生存时间。根据患者具体情况选择合适肺癌患者并进行吉非替尼治疗可望使肺癌治疗更为个体化,具有更好的临床应用前景。EGFR敏感突变可能能用来预测患者预后。
Objective
To investigate the factors that influence the long-term survival of patients with advanced non-small cell lung cancer(NSCLC) who were treated with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor. And detect the EGFR mutations of these long-term survival patients.
Methods
From December2002to June2007,292patients with advanced NSCLC were enrolled for treatment with EGFR-TKI in Peking Union Medical College Hospital. Clinical data was analyzed by Pearson's Chi-square test. Detect the EGFR mutations of the living patients in the serum samples by DNA sequencing method.
Results
The long-term survival of EGFR-TKI-treated patients had a3-year survival rate of16.1%, which was correlated with smoking history (P=0.033), and pathological type(P=0.006). It was not correlated with gender(P=0.311), age(P=0.121), ECOG score(P=0.299), and clinical stage(P=0.235). EGFR sensitive mutation rate in the serum of long-term survival patients was65.2%, and the mutation rates of female patients (68.8%) and adenocarcinoma patients were higher than the others.
Conclusions
EGFR-TKI offers a new treatment option for advanced NSCLC. EGFR mutation status may have important significance for evaluating the prognosis of advance NSCLC patients treated with EGFR-TKI.
引文
[1]Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002.[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]杨玲等,中国肺癌死亡趋势分析及发病、死亡的估计与预测,中国肺癌杂志2005年8月第8卷第4期。
[3]Non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials.[J]. BMJ,1995,311(7010):899-909.
[4]N. M. C. G. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol,2008,26, 4617-25
[5]Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.[J]. N Engl J Med,2002, 346(2):92-98.
[6]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[7]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[8]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000, 18(10):2095-2103.
[9]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353(2):123-132.
[10]Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict out come for bronchioloalveolar carcinoma. Ann Thorac Surg,2002;74:1640.
[11]Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer (Phila),1994; 73:1163.
[12]Sequist LV, Martins RG, Spigel D, et al, First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations, J Clin Oncol 2008:26;(15):2442-2449.
[13]Wang Y, Zhang X R, Zhu H X, et al. [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer] [J]. Zhonghua Yi Xue Za Zhi,2007,87(43):3069-3073.
[14]Wang B, Zhang X R, Chu D T. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer][J]. Zhonghua Zhong Liu Za Zhi,2007, 29(7):549-551.
[15]Wu Y L, Yang J J, Lin J Y, et al. [Gefitinib target treatment in non-small cell lung cancer][J]. Zhonghua Jie He He Hu Xi Za Zhi,2007,30(2):98-102.
[16]Huang H, Zhang Y, Zhao H Y, et al. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)][J]. Zhonghua Zhong Liu Za Zhi,2009, 31(2):148-151.
[17]Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer.[J]. Lung Cancer,2010,67(1):120-123.
[18]Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95.
[19]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
[20]Paez JG, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
[21]Tang X, Varella-Garcia M, Xavier AC, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
[22]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol, 2008,26(16):2745-2753.
[23]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[24]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[25]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009.[J]. CA Cancer J Clin, 2009,59(4):225-249.
[26]Douillard JY, Hirsch V, Mok T, Socinski MA, Watkins C, Lowe E,et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008;26(Suppl.):abs 8001.
[27]Xu J M, Han Y, Duan H Q, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.[J]. J Cancer Res Clin Oncol,2009,135(6):771-782.
[28]Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.[J]. J Natl Cancer Inst,2005,97(5):339-346.
[29]Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.[J]. Science,2004,304(5676):1497-1500.
[30]Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.[J]. Eur J Cancer,2006, 42(1):17-23.
[31]朱红,Tam Yee San Issan, Maria Wong. EGFR突变与非小细胞肺癌酪氨酸激酶抑制剂靶向治疗.中国肿瘤生物治疗杂志,2007,14(2)：105-109
[32]Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer 2007; 97:778-784.
[33]Moran T. et al. High correspondence between EGFR mutations in tissue and in circulating DNA from non-small cell lung cancer (NSCLC) patients (p) with poor performance status (PS).2007 edition of The Oncology Report Abstract 7505.
[34]Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stage IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27:2653-2659.
[35]Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second——line chemotherapy in advanced non-small-cell lung cancer:A randomized phase Ⅱ trial[J]. Ann Oncol.2005, 16(2):294.
[36]Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and cost——effectiveness of paelitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer[J]. Health Technol Assess,2001,5(32):191
[37]Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine:A muhicenter phaseⅠ/trial[J]. J Clin Oncol,1999,17(3):914
[38]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[39]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[40]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000, 18(10):2095-2103.
[41]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353 (2):123-132.
[42]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected][J]. J Clin Oncol,2003,21(12):2237-2246.
[43]Cufer T, Vrdoljak E, Gaafar R, et al. Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer.[J]. Anticancer Drugs,2006,17(4):401-409.
[44]Kim E S, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial.[J]. Lancet, 2008,372(9652):1809-1818.
[45]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med,2004; 350(21):2129.
[46]Dong Q, Huang J, Zhou Y, et al. Hematogenous dissemination of lung cancer cells during surgery:quantitative detection by flow cytometry and prognostic significance. Lung Cancer,2002;37(3):293.
[1]Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002.[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2008.[J]. CA Cancer J Clin,2008,58(2):71-96.
[3]Non-small cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials. [J]. BMJ,1995,311(7010):899-909.
[4]N M C G. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.[J]. J Clin Oncol,2008,26(28):4617-4625.
[5]Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.[J]. N Engl J Med,2002,346(2):92-98.
[6]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[7]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[8]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000,18(10):2095-2103.
[9]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353(2):123-132.
[10]Salomon D S, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. [J]. Crit Rev Oncol Hematol,1995,19(3):183-232.
[11]Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.[J]. Cancer Res,1993,53(10 Suppl):2379-2385.
[12]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected][J]. J Clin Oncol,2003,21(12):2237-2246.
[13]Nishiwaki Y, Yano S, Tamura T, et al. [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib][J]. Gan To Kagaku Ryoho,2004,31(4):567-573.
[14]Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer:a randomized trial.[J]. JAMA,2003,290(16):2149-2158.
[15]Guan Z Z, Zhang L, Li L Y, et al. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer:a clinical trial][J]. Ai Zheng,2005,24(8):980-984.
[16]Chen Y M, Perng R P, Tsai C M. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan:a prospective phase II study.[J]. J Chemother,2005,17(6):679-684.
[17]Cufer T, Vrdoljak E, Gaafar R, et al. Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or IV) non-small-cell lung cancer.[J]. Anticancer Drugs,2006,17(4):401-409.
[18]Maruyama R, Nishiwaki Y, Tamura T, et al. Phase Ⅲ study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.[J]. J Clin Oncol,2008,26(26):4244-4252.
[19]Kim E S, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial.[J]. Lancet,2008,372(9652):1809-1818.
[20]Lee D H, Park K, Kim J H, et al. Randomized Phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.[J]. Clin Cancer Res,2010,16(4):1307-1314.
[21]Giaccone G, Gonzalez-Larriba J L, van Oosterom A T, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.[J]. Ann Oncol,2004,15(5):831-838.
[22]Giaccone G, Herbst R S, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase III trial--INTACT 1.[J]. J Clin Oncol,2004,22(5):777-784.
[23]Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer:results of a west Japan thoracic oncology group trial (WJTOG0203).[J]. J Clin Oncol,2010,28(5):753-760.
[24]Hashizume T, Ogura T, Kozawa S, et al. [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer][J]. Gan To Kagaku Ryoho,2006,33(4):467-470.
[25]Lee D H, Han J Y, Yu S Y, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung:a prospective study.[J]. J Thorac Oncol,2006,1(9):965-971.
[26]Lin W C, Chiu C H, Liou J L, et al. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.[J]. Lung Cancer,2006,54(2):193-199.
[27]Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer:a phase Ⅱ study.[J]. J Clin Oncol,2006,24(1):64-69.
[28]Suzuki R, Hasegawa Y, Baba K, et al. A phase Ⅱ study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.[J]. Br J Cancer,2006,94(11):1599-1603.
[29]Mok T, Wu YL, Thongprasert S, Yang C-H, Chu D, Saijo N, et al.Phase Ⅲ, randomised, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer. Ann Oncol 2008;19(Suppl.8) (viiil, Abstract LBA2).
[30]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol,2008,26(16):2745-2753.
[31]Reck M, Buchholz E, Romer K S, et al. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage Ⅲ/Ⅳ non-small-cell lung cancer.[J]. Clin Lung Cancer,2006,7(6):406-411.
[32]Spigel D R, Hainsworth J D, Burkett E R, et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status:a Minnie Pearl Cancer Research Network Phase II Trial.[J]. Clin Lung Cancer,2005,7(2):127-132.
[33]Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.[J]. Lung Cancer,2004,43(3):317-322.
[34]D'Addario G, Rauch D, Stupp R, et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC):SAKK protocol 19/03.[J]. Ann Oncol,2008,19(4):739-745.
[35]Segawa Y, Hotta K, Umemura S, et al. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.[J]. Cancer,2006,107(8):1866-1872.
[36]Wang Y, Zhang X R, Zhu H X, et al. [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer] [J]. Zhonghua Yi Xue Za Zhi,2007,87(43):3069-3073.
[37]Wang B, Zhang X R, Chu D T. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer][J]. Zhonghua Zhong Liu Za Zhi,2007,29(7):549-551.
[38]Wu Y L, Yang J J, Lin J Y, et al. [Gefitinib target treatment in non-small cell lung cancer][J]. Zhonghua Jie He He Hu Xi Za Zhi,2007,30(2):98-102.
[39]Huang H, Zhang Y, Zhao H Y, et al. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)][J]. Zhonghua Zhong Liu Za Zhi,2009,31(2):148-151.
[40]Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer.[J]. Lung Cancer,2010,67(1):120-123.
[41]张力 缪若羽 李龙芸 王树兰 王孟昭.晚期非小细胞肺癌吉非替尼治疗3年生存因素分析[J].癌症进展,2009(02).
[42]Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.[J]. J Clin Oncol,2006,24(21):3340-3346.
[43]Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.[J]. Br J Cancer,2006,95(8):998-1004.
[44]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[45]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[46]Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase Ⅱ prospective study of the efficacy of gefitinib for the treatment of stage Ⅲ/Ⅳ non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. [J]. Lung Cancer,2007,56(3):383-389.
[47]Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.[J]. Proc Natl Acad Sci U S A,2004,101(36):13306-13311.
[48]Pao W, Miller V A, Politi K A, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.[J]. PLoS Med,2005,2(3):e73.
[49]Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.[J]. Cancer Res,2006,66(16):7854-7858.
[50]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol,2008,26(16):2745-2753.
[51]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[52]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase Ⅱ trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[53]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009.[J]. CA Cancer J Clin,2009,59(4):225-249.
[54]Douillard JY, Hirsch V, Mok T, Socinski MA, Watkins C, Lowe E,et al. Molecular and clinical subgroup analyses from a phase Ⅲ trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008;26(Suppl.):abs 8001.
[55]Xu J M, Han Y, Duan H Q, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.[J]. J Cancer Res Clin Oncol,2009,135(6):771-782.
[56]Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.[J]. J Natl Cancer Inst,2005,97(5):339-346.
[57]Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.[J]. Science,2004,304(5676):1497-1500.
[58]Sasaki H, Endo K, Takada M, et al. EGFR polymorphism of the kinase domain in Japanese lung cancer.[J]. J Surg Res,2008,148(2):260-263.
[59]Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.[J]. PLoS Med,2007,4(4):el25.
[60]Wu J Y, Yu C J, Yang C H, et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.[J]. Am J Respir Crit Care Med,2008,178(8):847-853.
[61]Yang C H. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia:present and future.[J]. Lung Cancer,2008,60 Suppl 2:S23-S30.
[62]Sasaki H, Okuda K, Takada M, et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.[J]. J Cancer Res Clin Oncol,2008,134(12):1371-1376.
[63]Bell D W, Brannigan B W, Matsuo K, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations:analysis of estrogen-related polymorphisms.[J]. Clin Cancer Res,2008,14(13):4079-4084.
[64]Kharrat N, Al'Fadhli S, Rebai M, et al. (AC) dinucleotide repeat polymorphism in intron 1 of human EGFR shows ethnic specificities and high evidence for association with breast cancer.[J]. Int J Biol Markers,2007,22(4):258-264.
[65]Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.[J]. J Clin Oncol,2006,24(14):2158-2163.
[66]Liu W, Innocenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.[J]. Clin Cancer Res,2003,9(3):1009-1012.
[67]Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.[J]. Eur J Cancer,2006,42(1):17-23.
[68]朱红,Tam Yee San Issan, Maria Wong. EGFR突变与非小细胞肺癌酪氨酸激酶抑制剂靶向治疗.中国肿瘤生物治疗杂志,2007,14(2)：105-109
[69]Kobayashi S, Boggon T J, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.[J]. N Engl J Med,2005,352(8):786-792.
[70]Bell D W, Gore I, Okimoto R A, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.[J]. Nat Genet,2005,37(12):1315-1316.
[71]Kobayashi S, Ji H, Yuza Y, et al. An altemative inhibitor over comes resistance caused by amutation ofthe epidermal growthfae-torreceptor[J]. Cancer Res,2005, 65:7096.
[2]杨玲等,中国肺癌死亡趋势分析及发病、死亡的估计与预测,中国肺癌杂志2005年8月第8卷第4期。
[3]Non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials.[J]. BMJ,1995,311(7010):899-909.
[4]N. M. C. G. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol,2008,26, 4617-25
[5]Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.[J]. N Engl J Med,2002, 346(2):92-98.
[6]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[7]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[8]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000, 18(10):2095-2103.
[9]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353(2):123-132.
[10]Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict out come for bronchioloalveolar carcinoma. Ann Thorac Surg,2002;74:1640.
[11]Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer (Phila),1994; 73:1163.
[12]Sequist LV, Martins RG, Spigel D, et al, First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations, J Clin Oncol 2008:26;(15):2442-2449.
[13]Wang Y, Zhang X R, Zhu H X, et al. [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer] [J]. Zhonghua Yi Xue Za Zhi,2007,87(43):3069-3073.
[14]Wang B, Zhang X R, Chu D T. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer][J]. Zhonghua Zhong Liu Za Zhi,2007, 29(7):549-551.
[15]Wu Y L, Yang J J, Lin J Y, et al. [Gefitinib target treatment in non-small cell lung cancer][J]. Zhonghua Jie He He Hu Xi Za Zhi,2007,30(2):98-102.
[16]Huang H, Zhang Y, Zhao H Y, et al. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)][J]. Zhonghua Zhong Liu Za Zhi,2009, 31(2):148-151.
[17]Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer.[J]. Lung Cancer,2010,67(1):120-123.
[18]Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95.
[19]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
[20]Paez JG, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
[21]Tang X, Varella-Garcia M, Xavier AC, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
[22]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol, 2008,26(16):2745-2753.
[23]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[24]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[25]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009.[J]. CA Cancer J Clin, 2009,59(4):225-249.
[26]Douillard JY, Hirsch V, Mok T, Socinski MA, Watkins C, Lowe E,et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008;26(Suppl.):abs 8001.
[27]Xu J M, Han Y, Duan H Q, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.[J]. J Cancer Res Clin Oncol,2009,135(6):771-782.
[28]Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.[J]. J Natl Cancer Inst,2005,97(5):339-346.
[29]Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.[J]. Science,2004,304(5676):1497-1500.
[30]Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.[J]. Eur J Cancer,2006, 42(1):17-23.
[31]朱红,Tam Yee San Issan, Maria Wong. EGFR突变与非小细胞肺癌酪氨酸激酶抑制剂靶向治疗.中国肿瘤生物治疗杂志,2007,14(2)：105-109
[32]Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer 2007; 97:778-784.
[33]Moran T. et al. High correspondence between EGFR mutations in tissue and in circulating DNA from non-small cell lung cancer (NSCLC) patients (p) with poor performance status (PS).2007 edition of The Oncology Report Abstract 7505.
[34]Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stage IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27:2653-2659.
[35]Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second——line chemotherapy in advanced non-small-cell lung cancer:A randomized phase Ⅱ trial[J]. Ann Oncol.2005, 16(2):294.
[36]Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and cost——effectiveness of paelitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer[J]. Health Technol Assess,2001,5(32):191
[37]Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine:A muhicenter phaseⅠ/trial[J]. J Clin Oncol,1999,17(3):914
[38]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[39]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[40]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000, 18(10):2095-2103.
[41]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353 (2):123-132.
[42]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected][J]. J Clin Oncol,2003,21(12):2237-2246.
[43]Cufer T, Vrdoljak E, Gaafar R, et al. Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer.[J]. Anticancer Drugs,2006,17(4):401-409.
[44]Kim E S, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial.[J]. Lancet, 2008,372(9652):1809-1818.
[45]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med,2004; 350(21):2129.
[46]Dong Q, Huang J, Zhou Y, et al. Hematogenous dissemination of lung cancer cells during surgery:quantitative detection by flow cytometry and prognostic significance. Lung Cancer,2002;37(3):293.
[1]Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002.[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2008.[J]. CA Cancer J Clin,2008,58(2):71-96.
[3]Non-small cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials. [J]. BMJ,1995,311(7010):899-909.
[4]N M C G. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.[J]. J Clin Oncol,2008,26(28):4617-4625.
[5]Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.[J]. N Engl J Med,2002,346(2):92-98.
[6]Fossella F V, Devore R, Kerr R N, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[J]. J Clin Oncol,2000,18(12):2354-2362.
[7]Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.[J]. J Clin Oncol,2004,22(9):1589-1597.
[8]Shepherd F A, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[J]. J Clin Oncol,2000,18(10):2095-2103.
[9]Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.[J]. N Engl J Med,2005,353(2):123-132.
[10]Salomon D S, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. [J]. Crit Rev Oncol Hematol,1995,19(3):183-232.
[11]Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.[J]. Cancer Res,1993,53(10 Suppl):2379-2385.
[12]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected][J]. J Clin Oncol,2003,21(12):2237-2246.
[13]Nishiwaki Y, Yano S, Tamura T, et al. [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib][J]. Gan To Kagaku Ryoho,2004,31(4):567-573.
[14]Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer:a randomized trial.[J]. JAMA,2003,290(16):2149-2158.
[15]Guan Z Z, Zhang L, Li L Y, et al. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer:a clinical trial][J]. Ai Zheng,2005,24(8):980-984.
[16]Chen Y M, Perng R P, Tsai C M. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan:a prospective phase II study.[J]. J Chemother,2005,17(6):679-684.
[17]Cufer T, Vrdoljak E, Gaafar R, et al. Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or IV) non-small-cell lung cancer.[J]. Anticancer Drugs,2006,17(4):401-409.
[18]Maruyama R, Nishiwaki Y, Tamura T, et al. Phase Ⅲ study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.[J]. J Clin Oncol,2008,26(26):4244-4252.
[19]Kim E S, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial.[J]. Lancet,2008,372(9652):1809-1818.
[20]Lee D H, Park K, Kim J H, et al. Randomized Phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.[J]. Clin Cancer Res,2010,16(4):1307-1314.
[21]Giaccone G, Gonzalez-Larriba J L, van Oosterom A T, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.[J]. Ann Oncol,2004,15(5):831-838.
[22]Giaccone G, Herbst R S, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase III trial--INTACT 1.[J]. J Clin Oncol,2004,22(5):777-784.
[23]Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer:results of a west Japan thoracic oncology group trial (WJTOG0203).[J]. J Clin Oncol,2010,28(5):753-760.
[24]Hashizume T, Ogura T, Kozawa S, et al. [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer][J]. Gan To Kagaku Ryoho,2006,33(4):467-470.
[25]Lee D H, Han J Y, Yu S Y, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung:a prospective study.[J]. J Thorac Oncol,2006,1(9):965-971.
[26]Lin W C, Chiu C H, Liou J L, et al. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.[J]. Lung Cancer,2006,54(2):193-199.
[27]Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer:a phase Ⅱ study.[J]. J Clin Oncol,2006,24(1):64-69.
[28]Suzuki R, Hasegawa Y, Baba K, et al. A phase Ⅱ study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.[J]. Br J Cancer,2006,94(11):1599-1603.
[29]Mok T, Wu YL, Thongprasert S, Yang C-H, Chu D, Saijo N, et al.Phase Ⅲ, randomised, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer. Ann Oncol 2008;19(Suppl.8) (viiil, Abstract LBA2).
[30]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol,2008,26(16):2745-2753.
[31]Reck M, Buchholz E, Romer K S, et al. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage Ⅲ/Ⅳ non-small-cell lung cancer.[J]. Clin Lung Cancer,2006,7(6):406-411.
[32]Spigel D R, Hainsworth J D, Burkett E R, et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status:a Minnie Pearl Cancer Research Network Phase II Trial.[J]. Clin Lung Cancer,2005,7(2):127-132.
[33]Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.[J]. Lung Cancer,2004,43(3):317-322.
[34]D'Addario G, Rauch D, Stupp R, et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC):SAKK protocol 19/03.[J]. Ann Oncol,2008,19(4):739-745.
[35]Segawa Y, Hotta K, Umemura S, et al. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.[J]. Cancer,2006,107(8):1866-1872.
[36]Wang Y, Zhang X R, Zhu H X, et al. [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer] [J]. Zhonghua Yi Xue Za Zhi,2007,87(43):3069-3073.
[37]Wang B, Zhang X R, Chu D T. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer][J]. Zhonghua Zhong Liu Za Zhi,2007,29(7):549-551.
[38]Wu Y L, Yang J J, Lin J Y, et al. [Gefitinib target treatment in non-small cell lung cancer][J]. Zhonghua Jie He He Hu Xi Za Zhi,2007,30(2):98-102.
[39]Huang H, Zhang Y, Zhao H Y, et al. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)][J]. Zhonghua Zhong Liu Za Zhi,2009,31(2):148-151.
[40]Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer.[J]. Lung Cancer,2010,67(1):120-123.
[41]张力 缪若羽 李龙芸 王树兰 王孟昭.晚期非小细胞肺癌吉非替尼治疗3年生存因素分析[J].癌症进展,2009(02).
[42]Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.[J]. J Clin Oncol,2006,24(21):3340-3346.
[43]Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.[J]. Br J Cancer,2006,95(8):998-1004.
[44]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[45]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[46]Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase Ⅱ prospective study of the efficacy of gefitinib for the treatment of stage Ⅲ/Ⅳ non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. [J]. Lung Cancer,2007,56(3):383-389.
[47]Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.[J]. Proc Natl Acad Sci U S A,2004,101(36):13306-13311.
[48]Pao W, Miller V A, Politi K A, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.[J]. PLoS Med,2005,2(3):e73.
[49]Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.[J]. Cancer Res,2006,66(16):7854-7858.
[50]Yang C H, Yu C J, Shih J Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.[J]. J Clin Oncol,2008,26(16):2745-2753.
[51]Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J]. J Clin Oncol,2008,26(15):2442-2449.
[52]Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase Ⅱ trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403).[J]. Br J Cancer,2008,98(5):907-914.
[53]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009.[J]. CA Cancer J Clin,2009,59(4):225-249.
[54]Douillard JY, Hirsch V, Mok T, Socinski MA, Watkins C, Lowe E,et al. Molecular and clinical subgroup analyses from a phase Ⅲ trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008;26(Suppl.):abs 8001.
[55]Xu J M, Han Y, Duan H Q, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.[J]. J Cancer Res Clin Oncol,2009,135(6):771-782.
[56]Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.[J]. J Natl Cancer Inst,2005,97(5):339-346.
[57]Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.[J]. Science,2004,304(5676):1497-1500.
[58]Sasaki H, Endo K, Takada M, et al. EGFR polymorphism of the kinase domain in Japanese lung cancer.[J]. J Surg Res,2008,148(2):260-263.
[59]Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.[J]. PLoS Med,2007,4(4):el25.
[60]Wu J Y, Yu C J, Yang C H, et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.[J]. Am J Respir Crit Care Med,2008,178(8):847-853.
[61]Yang C H. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia:present and future.[J]. Lung Cancer,2008,60 Suppl 2:S23-S30.
[62]Sasaki H, Okuda K, Takada M, et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.[J]. J Cancer Res Clin Oncol,2008,134(12):1371-1376.
[63]Bell D W, Brannigan B W, Matsuo K, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations:analysis of estrogen-related polymorphisms.[J]. Clin Cancer Res,2008,14(13):4079-4084.
[64]Kharrat N, Al'Fadhli S, Rebai M, et al. (AC) dinucleotide repeat polymorphism in intron 1 of human EGFR shows ethnic specificities and high evidence for association with breast cancer.[J]. Int J Biol Markers,2007,22(4):258-264.
[65]Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.[J]. J Clin Oncol,2006,24(14):2158-2163.
[66]Liu W, Innocenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.[J]. Clin Cancer Res,2003,9(3):1009-1012.
[67]Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.[J]. Eur J Cancer,2006,42(1):17-23.
[68]朱红,Tam Yee San Issan, Maria Wong. EGFR突变与非小细胞肺癌酪氨酸激酶抑制剂靶向治疗.中国肿瘤生物治疗杂志,2007,14(2)：105-109
[69]Kobayashi S, Boggon T J, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.[J]. N Engl J Med,2005,352(8):786-792.
[70]Bell D W, Gore I, Okimoto R A, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.[J]. Nat Genet,2005,37(12):1315-1316.
[71]Kobayashi S, Ji H, Yuza Y, et al. An altemative inhibitor over comes resistance caused by amutation ofthe epidermal growthfae-torreceptor[J]. Cancer Res,2005, 65:7096.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |